Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL104500 | 1.00 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Water SCHEMBL6764373 | 1.00 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Water SCHEMBL27861359 | 1.00 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Water SCHEMBL4025774 | 1.00 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Water SCHEMBL581158 | 1.00 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Water SCHEMBL27570711 | 1.00 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Water SCHEMBL18544564 | 1.00 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Fluoride SCHEMBL28787348 | 0.96 | CA2 (0.37) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL27892503 | 0.95 | CA2 (0.41) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL344 | 0.95 | CA2 (0.41) | CA2CES2ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423126-B1 | METHODS OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | JANSSEN BIOTECH INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4733320-A2 | METHODS OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260103510-A1 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | JANSSEN BIOTECH INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4714504-A2 | SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | THE UNIVERSITY OF CHICAGO (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2025262604-A1 | METHODS OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | JANSSEN BIOTECH, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-3762015-B1 | GUSELKUMAB FOR USE IN THE TREATMENT OF CROHN'S DISEASE WITH A DOSAGE REGIMEN | JANSSEN BIOTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3519049-B1 | SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL23 SPECIFIC ANTIBODY | JANSSEN BIOTECH INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250361720-A1 | WEB MATERIAL STRUCTURING BELT, METHOD FOR MAKING AND METHOD FOR USING | PROCTER & GAMBLE (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250340629-A1 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | JANSSEN BIOTECH INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3980065-A1 | SAFE AND EFFECTIVE METHOD OF TREATING PSORIATIC ARTHRITIS WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114341175-A | Non-classical MHC-containing nanoparticles and uses thereof | 乌第有限合伙公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3972994-A1 | NANOPARTICLES COMPRISING NON-CLASSICAL MHC AND USES THEREOF | UTI Limited Partnership (CA) | 2022-03-30 | — | — | EP | disclosed |
| US-20220089682-A1 | METHODS OF TREATING LIVER DISEASE | UTI LIMITED PARTNERSHIP (CA) | 2022-03-24 | — | — | US | disclosed |
| US-20220073603-A1 | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody | JANSSEN BIOTECH INC (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3958892-A1 | METHODS OF TREATING LIVER DISEASE | UTI Limited Partnership (CA) | 2022-03-02 | — | — | EP | disclosed |
| US-20220048985-A1 | Anti-IL-6 Antibody | JANSSEN BIOTECH INC (US) | 2022-02-17 | — | — | US | disclosed |
| CN-102471203-B | Process for preparation of hexafluoroacetone monohydrate | CENTRAL GLASS CO LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-102471203-A | Process for producing hexafluoroacetone monohydrate | CENTRAL GLASS CO LTD | 2012-05-23 | — | — | CN | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089682-A1 | METHODS OF TREATING LIVER DISEASE | CD74, HAVCR2, MICA | MEN1 4660/4885CA2 3166/4885CES2 1993/4885 |
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | FN1, MATR3, COL14A1 | MEN1 1152/4885CA2 4173/4885CES2 4849/4885 |
| US-20260103510-A1 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | IL23R, IL17A, IL15 | MEN1 3698/4885CA2 4736/4885CES2 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.